Detalhe da pesquisa
1.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
N Engl J Med
; 389(20): 1862-1876, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966285
2.
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB).
Alzheimers Dement
; 20(1): 695-708, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774088
3.
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
Ann Neurol
; 92(5): 729-744, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36151869
4.
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-ß monoclonal antibodies in dominantly inherited Alzheimer's disease.
Eur J Nucl Med Mol Imaging
; 50(9): 2669-2682, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37017737
5.
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Alzheimers Dement
; 19(6): 2287-2297, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454709
6.
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Alzheimers Dement
; 19(6): 2497-2507, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516028
7.
The impact of demographic, clinical, genetic, and imaging variables on tau PET status.
Eur J Nucl Med Mol Imaging
; 48(7): 2245-2258, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33215319
8.
Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Brain
; 142(4): 1063-1076, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753379
9.
Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.
Alzheimer Dis Assoc Disord
; 30(1): 1-7, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26885819
10.
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.
Alzheimers Dement
; 11(9): 1050-68, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25457431
11.
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.
JAMA Neurol
; 80(7): 749-756, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37213093
12.
Validation of 3- and 5-point severity scales to assess ARIA-E.
Alzheimers Dement (Amst)
; 15(4): e12503, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38026755
13.
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
JAMA Neurol
; 80(6): 614-623, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37155176
14.
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.
J Nucl Med
; 64(2): 294-303, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36137760
15.
Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state.
Eur J Hybrid Imaging
; 6(1): 2, 2022 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35039928
16.
Comparing ARIA-E severity scales and effects of treatment management thresholds.
Alzheimers Dement (Amst)
; 14(1): e12376, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36474747
17.
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
Alzheimers Res Ther
; 14(1): 178, 2022 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36447240
18.
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
JAMA Neurol
; 79(2): 149-158, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928318
19.
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
Alzheimers Dement (N Y)
; 8(1): e12306, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35676943
20.
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
JAMA Neurol
; 78(8): 961-971, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180956